Physician profile
Michelle M Muza-Moons
NPI 1215137161
$480,503.02
in general payments reported to CMS, 2019-2025
10 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $37K · 2023: $135K · 2024: $152K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $357K · Travel and Lodging: $47K · Consulting Fee: $27K · Food and Beverage: $11K · Education: $58.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $357,333.00 |
| Travel and Lodging | $47,377.59 |
| Consulting Fee | $27,097.50 |
| Food and Beverage | $10,642.98 |
| Education | $58.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421,504.23 | 2021-2025 | |
| Janssen Biotech, INC. | $51,282.86 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $5,161.96 | 2022-2024 | |
| Celgene Corporation | $1,855.55 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $468.39 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Boston Scientific Corporation | $155.91 | 2024 | Resolution 360 Clip |
| Lilly USA, LLC | $27.96 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $20.48 | 2023 | Dupixent |
| Olympus America INC. | $15.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Muza-Moons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.